Exelixis | Lånekapital



Loan Capital Endring Dato
Acadia Pharmaceuticals USD 0 0 2024-12
Agios Pharmaceuticals USD 0 0 2024-12
Amgen USD 56.55B 305M 2024-12
AstraZeneca USD 27.73B 2.29B 2024-12
Bayer EUR 34.55B 2.12B 2024-12
BioMarin Pharmaceutical USD 595.89M 1.27M 2024-12
Bristol-Myers Squibb USD 47.6B 1.07B 2024-12
Cytokinetics USD 645.6M 1.1M 2024-12
Eisai JPY 99.82B 9M 2024-12
Eli Lilly USD 28.53B 518.3M 2024-12
Exelixis USD 0 0 2025-01
Genmab DKK 937M 41M 2024-12
Glaxosmithkline GBP 14.64B 1.39B 2024-12
Incyte USD 33.54M 5.32M 2024-12
Ionis Pharmaceuticals USD 1.25B 11.67M 2024-12
MacroGenics USD 0 0 2024-12
Merck USD 34.46B 520M 2024-12
Moderna USD 39M 586M 2024-12
Neurocrine Biosciences USD 0 0 2024-12
Novartis USD 22.93B 2.41B 2024-12
Pfizer USD 57.4B 597M 2024-12
Sanofi 11.79B 712M 2024-12
Takeda JPY 4.7T 277.59B 2024-12
Ultragenyx Pharmaceutical USD 0 0 2024-12
Xencor USD 115.16M 104.99M 2024-12



Exelixis Lånekapital - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Apr 2025.